Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 247.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: -5.63%
• EPS Growth: 30.53%
• Country: SG
• Employees: 107
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.03
• Shares Outstanding: 1,231,494,600
• 10 Day Avg. Volume: 138,640
• 30 Day Avg. Volume: 247,960
• PEG Ratio: 0.04
• Price to Book (P/B): 0.55
• Price to Sales (P/S): 1.94
• P/FCF Ratio: -2.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: S$0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by financial performance challenges, including high leverage and negative profitability. Technical analysis provides some stability, but valuation concerns due to a negative P/E ratio and lack of dividend yield weigh on the score.

Singapore Institute of Advanced Medicine Holdings Ltd. Business Overview & Revenue Model

Company Description

Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company with interest in providing healthcare services. It offers pharmaceutical, surgical supplies and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011 and is headquartered in Singapore.

How the Company Makes Money

The company generates revenue primarily through its healthcare services, which include diagnostic imaging, radiotherapy, and oncology treatment. These services are offered to patients directly or through partnerships with hospitals and clinics. Revenue is also derived from collaborations with medical research institutions and healthcare providers, through which the company offers its specialized expertise and advanced technological solutions. The company's earnings are significantly bolstered by its strategic partnerships with technology providers, allowing them to access and implement the latest medical technologies, which attract more patients and healthcare partners. Additionally, they may receive funding or grants from governmental or private healthcare initiatives aimed at enhancing cancer treatment capabilities in the region.

Singapore Institute of Advanced Medicine Holdings Ltd. Financial Statement Overview

Summary

The company shows strong revenue growth but faces significant profitability challenges with negative net profit and EBIT margins. High leverage and negative returns on equity pose financial risks, despite improvements in free cash flow.

Income Statement

The company exhibits a strong revenue growth rate of 95.43% in the latest period, indicating a positive trajectory in sales. However, profitability remains a significant concern with negative net profit margins (-166.53%) and EBIT margins (-146.29%), suggesting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio of 1.05, indicating significant leverage which could pose financial risks. The return on equity is negative (-47.02%), reflecting poor profitability and returns for shareholders. The equity ratio stands at 44.61%, showing a moderate level of equity financing.

Cash Flow

The cash flow statement reveals a substantial free cash flow growth rate of 91.31%, which is a positive sign. However, the operating cash flow to net income ratio is negative (-0.62), indicating that the company is not generating sufficient cash from operations to cover its net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.71M	15.71M	16.65M	16.23M	13.81M	12.92M
Gross Profit	-8.52M	14.42M	15.36M	-2.60M	-4.31M	-2.32M
EBITDA	-11.04M	-11.08M	-13.42M	-10.78M	-8.02M	-3.06M
Net Income	-26.16M	-26.16M	-37.45M	-18.07M	-12.43M	-9.35M
Balance Sheet
Total Assets	124.71M	124.71M	138.76M	159.52M	174.36M	172.08M
Cash, Cash Equivalents and Short-Term Investments	2.84M	2.84M	3.16M	11.05M	15.84M	10.29M
Total Debt	58.21M	58.21M	46.10M	80.77M	87.30M	92.26M
Total Liabilities	69.07M	69.07M	57.01M	114.60M	120.31M	112.90M
Stockholders Equity	55.64M	55.64M	81.74M	44.93M	54.05M	59.18M
Cash Flow
Free Cash Flow	-11.08M	-10.78M	-14.80M	-19.89M	-11.26M	-9.72M
Operating Cash Flow	-10.93M	-10.63M	-14.26M	-5.45M	-7.15M	-4.26M
Investing Cash Flow	112.97K	113.13K	-263.72K	-1.45M	3.72M	-5.25M
Financing Cash Flow	10.50M	10.20M	6.64M	2.11M	9.18M	10.66M

Singapore Institute of Advanced Medicine Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:9G2, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.03, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.46 is Neutral, neither overbought nor oversold. The STOCH value of 38.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:9G2.

Singapore Institute of Advanced Medicine Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSL	65 Neutral	S$1.88B	29.15	6.20%	2.50%	8.90%	4.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9G2	48 Neutral	―	―	-39.37%	―	-5.63%	30.53%

Singapore Institute of Advanced Medicine Holdings Ltd. Corporate Events

Singapore Institute of Advanced Medicine Streamlines Decision-Making Process

The Singapore Institute of Advanced Medicine Holdings Ltd. has dissolved its Strategic Review Committee (SRC) as of August 8, 2025. The Board of Directors will now directly handle the functions and recommendations previously managed by the SRC to streamline decision-making and expedite the implementation of initiatives.